Skip to content
DataLookout
Menu

NCT07927478

Transcutaneous Auricular Vagal Neuromodulation Therapy (AVNT™) in Chronic Kidney Disease Autonomic Dysfunction

StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Change in Orthostatic Heart Rate Response
Timeframe: Week 0, Week 2

Secondary (6)

Change in high-sensitivity C-reactive protein (hs-CRP) (pg/mL)
Change in Interleukin-6 (IL-6) (pg/mL)
Change in Urine Albumin-Creatinine Ratio (UACR) (mg/g creatinine)
Change in Composite Autonomic Symptom Score-31 (COMPASS-31)
Percentage of participants who achieved ≥85% prescribed minutes (714 of 840 min)
Show 1 moreShow less
Percentage of patients that completed ≥70% of scheduled autonomic measurements

Arms and interventions

Sham-AMSham comparator

Participants will use the sham-device for 1 hr/day at 7:00 AM.

Sham-PMSham comparator

Participants will use the sham-device for 1 hr/day at 7:00 PM.

Active-AMExperimental

Participants will use the active AVNT device for 1 hr/day at 7:00 AM.

Active-PMExperimental

Participants will use the active AVNT device for 1 hr/day at 7:00 PM.

Devices: Auricular Vagal Neuromodulation Therapy (AVNT™), Sham-device

Sites

1 site in 1 country

  • NYU Langone HealthNew York, New York, United States